These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7061487)

  • 41. [Anticoagulating activity and lytic action of the heparin-antithrombin III and antithrombin III-heparin-thrombin complexes on non-stabilized fibrin].
    Kudriashov BA; Pastorova VE; Liapina LA
    Biokhimiia; 1981 Nov; 46(11):2024-9. PubMed ID: 7317530
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of sulfation on the anticoagulant and antithrombin III-binding properties of a heparin fraction with low affinity for antithrombin III.
    Schoen P; Wielders S; Petitou M; Lindhout T
    Thromb Res; 1990 Feb; 57(3):415-23. PubMed ID: 2315894
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of oral anticoagulant treatment on plasma and serum antithrombin III: a study on 172 patients at different levels of anticoagulation.
    De Stefano V; Leone G; De Martini D; Di Donfrancesco A; Accorrà F; Bizzi B
    Haemostasis; 1987; 17(4):195-200. PubMed ID: 3114102
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition of factor IXa and factor Xa by antithrombin III/heparin during factor X activation.
    Pieters J; Willems G; Hemker HC; Lindhout T
    J Biol Chem; 1988 Oct; 263(30):15313-8. PubMed ID: 3262615
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A coagulation pathway on bovine aortic segments leading to generation of Factor Xa and thrombin.
    Stern DM; Nawroth PP; Kisiel W; Handley D; Drillings M; Bartos J
    J Clin Invest; 1984 Dec; 74(6):1910-21. PubMed ID: 6439737
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Separation of active and inactive forms of human antithrombin by heparin affinity chromatography.
    Heger A; Grunert T; Schulz P; Josic D; Buchacher A
    Thromb Res; 2002 Apr; 106(2):157-64. PubMed ID: 12182916
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structure and biological activity of finback-whale (Balaenoptera physalus L.) heparin octasaccharide. Chemical, carbon-13 nuclear-magnetic-resonance, enzymic and biological studies.
    Ototani N; Kikuchi M; Yosizawa Z
    Biochem J; 1982 Jul; 205(1):23-30. PubMed ID: 7126178
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Heparin-catalyzed inhibitor/protease reactions: kinetic evidence for a common mechanism of action of heparin.
    Griffith MJ
    Proc Natl Acad Sci U S A; 1983 Sep; 80(18):5460-4. PubMed ID: 6577437
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Influence of chemical modification of tryptophan residues on the properties of human antithrombin III.
    Shah N; Scully MF; Ellis V; Kakkar VV
    Thromb Res; 1990 Feb; 57(3):343-52. PubMed ID: 2315891
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The relative molecular mass dependence of the anti-factor Xa properties of heparin.
    Ellis V; Scully MF; Kakkar VV
    Biochem J; 1986 Sep; 238(2):329-33. PubMed ID: 3800942
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Two-dimensional affinity resolution electrophoresis demonstrates that three distinct heparin populations interact with antithrombin III.
    Edens RE; Fromm JR; Fromm SJ; Linhardt RJ; Weiler JM
    Biochemistry; 1995 Feb; 34(8):2400-7. PubMed ID: 7873519
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro and in vivo studies of the anti-Xa activity of heparin.
    Eggleton CA; Barrowcliffe TW; Merton RE; Thomas DP
    Thromb Res; 1981 Nov; 24(4):319-28. PubMed ID: 7336385
    [No Abstract]   [Full Text] [Related]  

  • 53. Heparin-antithrombin III binding. In vitro and in vivo studies.
    Chan V; Chan TK
    Haemostasis; 1979; 8(6):373-89. PubMed ID: 511016
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biologic studies on chemically synthesized pentasaccharide and tetrasaccharide fragments.
    Choay J
    Semin Thromb Hemost; 1985 Apr; 11(2):81-5. PubMed ID: 4035368
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of factor X and factor V activation by dermatan sulfate and a pentasaccharide with high affinity for antithrombin III in human plasma.
    Ofosu FA; Choay J; Anvari N; Smith LM; Blajchman MA
    Eur J Biochem; 1990 Oct; 193(2):485-93. PubMed ID: 2226466
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antithrombin III Toyama: a congenital antithrombin III abnormality with recurrent thrombophlebitis.
    Takahashi K; Kondo S; Sakuragawa N
    Nihon Ketsueki Gakkai Zasshi; 1985 Dec; 48(8):1895-905. PubMed ID: 3836552
    [No Abstract]   [Full Text] [Related]  

  • 57. Isolation and partial characterization of two distinct types of antithrombin III from rabbit.
    Carlson TH; Atencio AC
    Thromb Res; 1982 Jul; 27(1):23-34. PubMed ID: 7123512
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of urokinase by complex formation with human antithrombin III in absence and presence of heparin.
    Clemmensen I
    Thromb Haemost; 1978 Jun; 39(3):616-23. PubMed ID: 705690
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterization of rat factors X and Xa: demonstration of factor Xa in rat plasma.
    Enjyoji K; Miyazaki K; Kato H
    J Biochem; 1991 Jun; 109(6):890-8. PubMed ID: 1718949
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Further characterization of a pathological isoantithrombin with no affinity for heparin (antithrombin III Roma).
    De Stefano V; Leone G; Ferrelli R; Di Donfrancesco A; De Martini D; Bizzi B
    Thromb Res; 1987 Oct; 48(1):23-30. PubMed ID: 3424283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.